Today’s FDA approval of Skinvive by Juvéderm for the reduction of horizontal neck lines marks a significant milestone in aesthetic dermatology, and one I have had the privilege of contributing to directly as lead author and principal investigator of the pivotal clinical trial that established the foundational evidence base for this product.
Our randomized, multicenter, evaluator-blinded study, published in Dermatologic Surgery in 2023, evaluated the safety and effectiveness of VYC-12L for skin quality improvements and provided the clinical data that supported Skinvive by Juvéderm’s initial FDA approval for cheek skin smoothness.
The mechanism of action distinguishes this product categorically from traditional hyaluronic acid fillers. Rather than augmenting volume, VYC-12L is delivered as micro-droplets intradermally, where it restores the skin’s intrinsic capacity to retain moisture, resulting in measurably improved softness, hydration and smoothness. This is a fundamentally different therapeutic paradigm — one that addresses skin quality at the dermal level rather than structural contour.
The extension of this approval to horizontal neck lines is both scientifically logical and clinically timely. The neck has long been one of the most undertreated areas in aesthetic medicine, owing in part to the absence of FDA-approved injectable options specifically indicated for this anatomical zone.
